Researchers found that two new treatments, Foundayo and a lower dose of Zepbound, can help people maintain their weight loss after transitioning from higher doses of existing injectable therapies. In clinical trials, participants who switched from Wegovy to Foundayo maintained nearly all their weight loss after one year, losing only 0.9 kg on average. Similarly, those who switched from Zepbound maintained about 5 kg of their weight loss. This is significant because many people struggle with weight regain after stopping or switching treatments, making these findings particularly relevant for anyone looking to sustain their weight loss journey.

This research is crucial for individuals dealing with obesity or overweight, as it highlights effective long-term options for weight maintenance. The studies involved hundreds of participants who had already lost weight using higher doses of these medications. The results suggest that both Foundayo and Zepbound can provide a reliable way to keep off the pounds, which is essential for improving overall health, reducing the risk of obesity-related conditions, and enhancing quality of life.

The evidence comes from large, late-phase trials, indicating a strong level of confidence in these findings. Both the ATTAIN-MAINTAIN and SURMOUNT-MAINTAIN trials showed that these treatments effectively helped participants maintain their weight loss over a year. While the safety profiles of Foundayo and Zepbound were consistent with previous studies, it’s important to note that these medications should be used alongside a healthy diet and exercise for the best results.

For those considering these options, it’s advisable to consult with a healthcare provider to discuss the most suitable approach tailored to individual health needs and weight-loss goals.

Source: investor.lilly.com